Form 4: Sage Therapeutics Executive Laura Gault Reports Stock Transaction
SEC Form 4 Filing
Chief Medical Officer Laura Gault of Sage Therapeutics reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 13, 2025, Laura Gault, Chief Medical Officer of Sage Therapeutics, had 685 shares of common stock withheld to cover tax obligations.
- This was due to the vesting of 2,813 shares of time-based restricted stock units (RSUs) granted on February 13, 2024, under the company's 2014 Stock Option and Incentive Plan.
- Following the transaction, Gault directly owns 34,649 shares of Sage Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a routine stock transaction related to executive compensation.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| November 1, 2024 | Date of Power of Attorney authorization for Chris Benecchi, Greg Shiferman, Brandon Marsh and Stuart Falber to act on Laura Gault's behalf for SEC filings. |
| February 13, 2024 | Date of grant for the restricted stock units (RSUs) that vest over four years. |
| February 13, 2025 | Date of the stock transaction where shares were withheld to cover tax obligations upon vesting of RSUs. |
| February 14, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.